Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.75 |
| ▸ | TRPM8 | Q7Z2W7 | 7/20 | 0.57 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12381600 | 1.00 | EPHX1 (0.75) | EPHX1TRPM8TRPA1TRPV1KCNA5 | |
| SCHEMBL2057748 | 1.00 | EPHX1 (0.75) | EPHX1TRPM8TRPA1TRPV1KCNA5 | |
| SCHEMBL10001728 | 1.00 | EPHX1 (0.75) | EPHX1TRPM8TRPA1TRPV1KCNA5 | |
| SCHEMBL6128506 | 1.00 | EPHX1 (0.75) | EPHX1TRPM8TRPA1TRPV1KCNA5 | |
| SCHEMBL291653 | 1.00 | EPHX1 (0.75) | EPHX1TRPM8TRPA1TRPV1KCNA5 | |
| SCHEMBL22361298 | 0.89 | EPHX1 (0.72) | EPHX1TRPM8TRPA1TRPV1KCNA5 | |
| Hexane SCHEMBL28846476 | 0.89 | EPHX1 (0.62) | EPHX1TRPM8TRPA1TRPV1 | |
| SCHEMBL10001727 | 0.88 | EPHX1 (0.70) | EPHX1TRPM8TRPA1TRPV1KCNA5 | |
| SCHEMBL6128484 | 0.88 | EPHX1 (0.70) | EPHX1TRPM8TRPA1TRPV1KCNA5 | |
| SCHEMBL10034575 | 0.88 | EPHX1 (0.70) | EPHX1TRPM8TRPA1TRPV1KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120116113-A1 | PROCESS FOR MAKING NEO-ENRICHED p-MENTHANE COMPOUNDS | RENESSENZ LLC | 2012-05-10 | — | — | US | disclosed |
| US-7772266-B2 | treating or preventing benign prostatic hyperplasia, enlarged prostate, acute urinary retention with 2-Isopropyl-5-methyl-cyclohexanecarboxylic acid (2-amino-2-phenyl-ethyl)-amide; agonists or antagonists of a transient receptor potential proteins; anticarcinogenic agent | DENDREON CORPORATION (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772266-B2 | treating or preventing benign prostatic hyperplasia, enlarged prostate, acute urinary retention with 2-Isopropyl-5-methyl-cyclohexanecarboxylic acid (2-amino-2-phenyl-ethyl)-amide; agonists or antagonists of a transient receptor potential proteins; anticarcinogenic agent | DENDREON CORPORATION (US) | 2010-08-10 | — | — | US | disclosed |
| US-20080255185-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255185-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255185-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | TRPC4, TRPC3, TRPC1 | EPHX1 2888/4885TRPM8 7/4885TRPA1 22/4885 |
| US-20120116113-A1 | PROCESS FOR MAKING NEO-ENRICHED p-MENTHANE COMPOUNDS | ME3, MDH2, ME2 | EPHX1 238/4885TRPM8 571/4885TRPA1 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.